Initially, the High Flux Reactor, was primarily intended to be used for materials research. Past research focussed on the resistence of materials to irradiation with neutrons. Especially materials for fusion and fission reactors were evaluated and tested to enhance reliability of components. Today it is an indispensible facility for the production of radio-isotopes for the medical sectors, covering some 60% of European demand. In addition it plays a key role in international (nuclear) research projects, among which are projects on materials for fusion reactors.

The High Flux Reactor (HFR) is in operation since 1963 and is owned by the Joint Research Center (JRC) of the European Union in Petten. The research reactor has a thermal power of 45 MW. NRG is the licensee. The reactor is operated and maintained by NRG-staff.

NRG  is planning to build the PALLAS reactor in order to replace the HFR. This new nuclear reactor will guarantee the production of medical isotopes and the continuation of nuclear research into the future. The HFR is reaching the end of its economic life. PALLAS will be equipped to meet the growing world demand for medical isotopes and nuclear knowledge and services more efficiently and effectively. The PALLAS reactor has been named after the Greek goddess of wisdom, knowledge and patroness of art and science.

More information on PALLAS can be found on its website: www.pallasreactor.eu